Aceso Life Science Group Balance Sheet Health
Financial Health criteria checks 3/6
Aceso Life Science Group has a total shareholder equity of HK$2.2B and total debt of HK$2.8B, which brings its debt-to-equity ratio to 125.3%. Its total assets and total liabilities are HK$5.3B and HK$3.1B respectively.
Key information
125.3%
Debt to equity ratio
HK$2.80b
Debt
| Interest coverage ratio | n/a |
| Cash | HK$341.00m |
| Equity | HK$2.23b |
| Total liabilities | HK$3.07b |
| Total assets | HK$5.30b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 474's short term assets (HK$1.5B) do not cover its short term liabilities (HK$2.3B).
Long Term Liabilities: 474's short term assets (HK$1.5B) exceed its long term liabilities (HK$782.0M).
Debt to Equity History and Analysis
Debt Level: 474's net debt to equity ratio (110.1%) is considered high.
Reducing Debt: 474's debt to equity ratio has increased from 89.7% to 125.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 474 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 474 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18% per year.